Publications by authors named "Annabel Alig"

Claim this Profile
F
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).
Lena Weiss, Sebastian Stintzing, Dominik Paul Modest, Arndt Stahler, Ludwig Fischer von Weikersthal, Annabel Alig

Eur J Cancer· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
<
Deep Learning-derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-Type Metastatic Colorectal Cancer.
Julius Keyl, René Hosch, Fabian Hörst, Philipp Keyl, Amin Dada, Annabel H S Alig

Clin Cancer Res· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Management of mismatch repair-deficient tumors].
Sebastian Stintzing, Annabel Alig, Dominik Modest, Ivan Jelas, Arndt Stahler

Inn Med (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic status and therapy-dependent survival in pancreatic cancer patients.
François Schneider, Haotian Chen, Uwe Pelzer, Richard G Compton, Gregor Duwe, Annabel Alig

Eur J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials.
Alexej Ballhausen, Federica Morano, Arndt Stahler, Sara Lonardi, Andreas Jay Kind, Annabel Helga Sophie Alig

Br J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial.
Alexej Ballhausen, Susanna Swoboda, David Horst, Stefan Fruehauf, Ullrich Graeven, Annabel Helga Sophie Alig

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pancreatic Cancer Highlights from the European Society for Medical Oncology Annual Meeting 2024 in Barcelona.
Sabrina Sulzer, Marianne Sinn, Annabel Helga Sophie Alig, Anna Maxi Wandmacher

Oncol Res Treat· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary cardiac sarcoma: insights from two decades of multimodal management at LMU Munich.
Anton Burkhard-Meier, Dorit Di Gioia, Vindi Jurinovic, Michael Hoberger, Sinan E Güler, Annabel H S Alig

Cardiooncology· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.
Lena Weiss, Sebastian Stintzing, Arndt Stahler, C Benedikt Westphalen, Ludwig Fischer von Weikersthal, Annabel Alig

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highlights of Translational and Molecular Research Presented at the European Society for Medical Oncology Annual Meeting 2024.
Carolin Krekeler, Verena Turco, Annabel Helga Sophie Alig, Annalen Bleckmann, Michael Quante

Oncol Res Treat· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial.
Arndt Stahler, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Müller, Annabel H S Alig

EClinicalMedicine· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123).
David Witte, Ina Pretzell, Timm M Reissig, Alexander Stein, Janna-Lisa Velthaus, Annabel Alig

J Cancer Res Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116).
Dominik Paul Modest, Volker Heinemann, Philipp Schütt, Stefan Angermeier, Mike Haberkorn, Annabel Helga Sophie Alig

J Cancer Res Clin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highlights of Translational and Molecular Research Presented at the European Society for Medical Oncology Annual Meeting 2023.
Maria Pouyiourou, Lea Elisabeth Reitnauer, Alexej Ballhausen, Annabel Helga Sophie Alig, Annalen Bleckmann

Oncol Res Treat· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
Greta Sommerhäuser, Meinolf Karthaus, Annika Kurreck, Alexej Ballhausen, Johanna W Meyer-Knees, Annabel H S Alig

Int J Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent Intracranial Ewing Sarcoma.
Soo Ann Yap, Annabel Helga Sophie Alig, Alena Annbalou Hasenburg, Georg Hilfenhaus, Lars Uwe Stephan

Ochsner J· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
Alexej Ballhausen, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Müller, Annabel Helga Sophie Alig

Eur J Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212).
Arndt Stahler, Beeke Hoppe, Il-Kang Na, Luisa Keilholz, Lothar Müller, Annabel Helga Sophie Alig

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Greta Sommerhäuser, Annika Kurreck, Alexander Beck, Uli Fehrenbach, Meinolf Karthaus, Annabel H S Alig

Eur J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The feasibility of electromagnetic sensing aided post pyloric feeding tube placement (CORTRAK) in patients with thrombocytopenia with or without anticoagulation on the intensive care unit.
Stephanie Susanne Stecher, Michaela Barnikel, Heidrun Drolle, Alexandra Pawlikowski, Johanna Tischer, Annabel Alig

JPEN J Parenter Enteral Nutr· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-up lung ultrasound to monitor lung failure in COVID-19 ICU patients.
Michaela Barnikel, Annabel Helga Sophie Alig, Sofia Anton, Lukas Arenz, Henriette Bendz

PLoS One· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.
Nathanael Raschzok, Sebastian Stintzing, Volker Heinemann, Geraldine Rauch, Jens Ricke, Annabel H S Alig

BMC Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial.
Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Florian Kaiser, Annabel Helga Sophie Alig

Front Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy.
Annabel H S Alig, Volker Heinemann, Michael Geissler, Ludwig Fischer von Weikersthal, Thomas Decker

Cancers (Basel)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Arndt Stahler, Volker Heinemann, Julian Walter Holch, Jobst Christian von Einem, Christoph Benedikt Westphalen, Annabel Helga Sophie Alig

Int J Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis